David S. Siegel, M.D., Ph.D.

David S. Siegel, M.D., Ph.D., chief of the Division of Multiple Myeloma is one of the nation's foremost authorities on multiple myeloma, a blood cancer. Most recently, Dr. Siegel served the lead investigator of the pivotal multi-center, phase IIb study involving 30 cancer centers in North America that led to the FDA's fast-track approval of Kyprolis (carfilzomib) for relapsed multiple myeloma patients

Dr. Siegel is one of 11 investigators nationwide who brought the exciting new chemotherapeutic agent Velcade to multiple myeloma patients through his clinical trials with the medication. Velcade is an injectable drug that blocks some of the chemical pathways associated with unregulated cancer cell growth. Dr. Siegel's studies have shown that Velcade slows and halts the progression of multiple myeloma. He has also been involved in clinical trials for chemotherapeutic agents Revlimid and Carfilzomib. Dr. Siegel's research has almost exclusively focused on multiple myeloma and has been published in many leading medical journals, including Nature, New England Journal of Medicine, Blood and Journal of Clinical Oncology.

Dr. Siegel is a member of the
Multiple Myeloma Research Consortium (MMRC) Steering Committee.  The MMRC is a unique research model that was developed to accelerate the development of novel, cutting-edge treatments for patients afflicted by multiple myeloma by catalyzing, promoting, and facilitating collaborative research between industry and academia. Click here for a list of John Theurer Cancer Center Multiple Myeloma clinical trials.

Dr. Siegel Discusses New Breakthrough Treatments for Patients in WSJ